卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素

doi:10.6040/j.issn.1671-7554.0.2018.223

摘要/Abstract

摘要： 目的探讨卵巢支持间质细胞肿瘤(SLCT)患者保留生育功能治疗的预后及其相关因素。方法回顾性分析北京协和医院52例保留生育功能治疗的卵巢SLCT患者的生存率、复发、死亡与生育状况等。结果临床表现中,41例有高雄激素表现,11例无内分泌表现。全部肿瘤均位于单侧卵巢;肿瘤最大径线2~34 cm,平均10 cm;Ⅰ期50例(ⅠA期36例,ⅠC期14例),ⅢC期1例,分期不明1例;高分化4例(7.7%),中分化14例(26.9%),低分化34例(65.4%),低分化者中含有网状结构者9例、含异源成分者4例。初次手术方式包括仅行肿瘤剔除6例(11.5%),患侧附件切除36例(69.2%),全面分期手术10例(19.2%)。初治术后29例接受化疗1~4个疗程。平均随访72个月,6例复发,3例死亡。预后差与无内分泌表现、肿瘤大、分期高于ⅠA期有关,与低分化、网型或异源成分可能相关,与手术方式及术后是否化疗无关。结论卵巢SLCT是一种少见的卵巢性索间质肿瘤,多数患者以男性化临床表现和盆腔包块为特征,无内分泌表现者恶性程度较高,预后与肿瘤大小、临床分期有关,与组织分化程度可能相关。年轻患者可采取保留生育功能的手术,对有高危因素及复发患者建议术后辅助化疗并长期随访。

关键词: 卵巢支持间质细胞肿瘤, 保留生育功能治疗, 预后

Abstract: Objective To evaluate the prognosis and its related factors of patients with ovarian Sertoli-Leydig cell tumor(SLCT)after fertility-preserving surgery. Methods Detail clinical data, including survival rates, recurrence, death and fertility states, of 52 SLCT patients after fertility-preserving surgery in Peking Union Medical College Hospital were retrospectively reviewed. Results Forty-one cases showed androgenic manifestations, while 11 cases had no endocrine symptoms. All tumors located in unilaterl ovary; the mean tumor diameter was 10.0 cm(range 2-34 cm); fifty cases were at stage Ⅰ(36 cases at stage ⅠA, 14 cases at stage ⅠC), one was at stage ⅢC, ones stage was unknown; four(7.7%)tumors were well differentiated, 14(26.9%)were intermediately differentiated, 34(65.4%)were poorly differentiated. In the poorly differentiated tumors, 9 had a retiform pattern, 4 had heterologous elements. Six patients(11.5%)underwent cystectomy, 36(69.2%)underwent unilateral salpingo-oophorectomy, and 10(19.2%)underwent standard staging surgery. Twenty-nine patients received systematic chemotherapy(1-4 courses of treatment)after 山东大学学报 (医学版)56卷5期 -杨旎,等.卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素 \=-the initial surgery. The average follow-up period was 72 months; six cases recurred, in whom 3 cases died. The poor prognosis was correlated with no endocrine symptoms, bigger tumor size, clinical stage >ⅠA, and probably correlated with poor differentiation, retiform pattern and heterologous elements, while not correlated with surgery type and postoperative chemotherapy. Conclusion SLCT is a rare type of sex cord-stromal tumor of the ovary. Most SLCT patients have androgenic manifestations and abdominal masses, and tumors without endocrine changes may indicate more aggressive biological behaviors. The prognosis is correlated with tumor size and clinical stage, and probably correlated with the degree of differentiation. Conservative surgery is acceptable for young patients wishing to preserve fertility, and postoperative adjuvant chemotherapy and long-term follow up are recommended to those with high-risk factors of recurrence.

Key words: Ovarian Sertoli-Leydig cell tumor, Fertility-preserving therapy, Prognosis

中图分类号:

R711.75

杨旎,曹冬焱,杨佳欣,游燕,沈铿. 卵巢支持间质细胞肿瘤保留生育功能治疗的预后及相关因素[J]. 山东大学学报 (医学版), 2018, 56(5): 30-34.

YANG Ni, CAO Dongyan, YANG Jiaxin, YOU Yan, SHEN Keng. Prognosis related factors of patients with ovarian Sertoli-Leydig cell tumor after fertility-preserving surgery[J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 30-34.

参考文献

[1] Lantzsch T, Stoerer S, Lawrenz K, et al. Sertoli-Leydig cell tumor[J]. Arch Gynecol Obstet, 2001, 264(4): 206-208.
[2] Young RH, Scully RE. Ovarian Sertoli-Leydig cell tumors. A clinicopathological analysis of 207 cases[J]. Am J Surg Pathol, 1985, 9(8): 543-569.
[3] Shu H, Yang X, Gao AF. Ovarian Sertoli-Leydig cell tumor in a 9-month-old infant with special histologic pattern[J]. Fetal Pediatr Pathol, 2012, 31(6): 388-393.
[4] Bhat RA, Lim YK, Chia YN, et al. Sertoli-Leydig cell tumor of the ovary: analysis of a single institution database[J]. J Obstet Gynaecol Res, 2013, 39(1): 305-310.
[5] Weng CS, Chen MY, Wang TY, et al. Sertoli-Leydig cell tumors of the ovary: a Taiwanese Gynecologic Oncology Group study[J]. Taiwan J Obstet Gynecol, 2013, 52(1): 66-70.
[6] Abu-Zaid A, Azzam A, Alghuneim LA, et al. Poorly differentiated ovarian sertoli-leydig cell tumor in a 16-year-old single woman: a case report and literature review[J]. Case Rep Obstet Gynecol, 2013: 858501.
[7] Chang RJ, Dumesic DA. Polycystic ovary syndrome and hyperandrogenic states. In: Yen, Samuel SC, ed. Yen & Jaffes reproductive endocrinology[M]. 5th ed. Philadelphia: Elsevier Saunders, 2004: 597-632.
[8] 肖会廷,李斌,李晓光,等.卵巢支持莱迪细胞瘤15例临床病理分析[J].实用妇产科杂志, 2011, 27(12): 933-936. XIAO Huiting, LI Bin, LI Xiaoguang, et al. Ovarian Sertoli-Leydig cell tumors: clinical pathologic features of 15 cases[J]. J Practical Obstet Gynecol, 2011, 27(12): 933-936.
[9] Chen L, Tunnell CD, De Petris G. Sertoli-Leydig cell tumor with heterologous element: a case report and a review of the literature[J]. Int J Clin Exp Pathol, 2014, 7(3): 1176-1181.
[10] Roth LM, Anderson MC, Govan AD, et al. Sertoli-Leydig cell tumors: a clinicopathologic study of 34 cases[J]. Cancer, 1981, 48(1): 187-197.
[11] Grove A, Vestergaard V. Ovarian Sertoli-Leydig cell tumor of intermediate grade with heterologous elements of rhabdomyosarcoma. A case report and a review of the literature[J]. Ann Diagn Pathol, 2006, 10(5): 288-293.
[12] Liggins CA, Ma LT, Schlumbrecht MP. Sertoli-Leydig cell tumor of the ovary: a diagnostic dilemma[J]. Gynecol Oncol Rep, 2015, 15: 16-19.
[13] Zhang M, Cheung MK, Shin JY, et al. Prognostic factors responsible for survival in sex-cord stromal tumors of the ovary—an analysis of 376 women[J]. Gynecol Oncol, 2007, 104(2): 396-400.
[14] Schneider DT, Harms D, Calaminus G. Ovarian sex cord stromal tumors in children and adolescents[J]. J Reprod Med, 2005, 50(6): 439-446.
[15] Appetecchia M, Cela V Bernardi F, Burelli A, et al. Sertoli-Leydig cell androgens-estrogens secreting tumor of the ovary: ultra-conservnive surgery[J]. Eur J Obstet Gynecol Reprod Biol, 2004, 116(1): 113-116.
[16] Sahoo TK, Kar T, Kar A, et al. Poorly differentiated Sertoli-Leydig cell tumour of ovary with heterologous elements[J]. J Clin Diagn Res, 2017, 11(5): XD01-XD02.
[17] Sigismondi C, Gadducci A, Lorusso D, et al. Ovarian Sertoli-Leydig cell tumors. A retrospective MITO study[J]. Gynecol Oncol, 2012, 125(3): 673-676.
[18] Litta P, Saccardi C, Conte L, et al. Sertoli-Leydig cell tumors: current status of surgical management: literature review and proposal of treatment[J]. Gynecol Endocrinol, 2013, 29(5): 412-417.

相关文章 15

[1]	李梓绮,魏闫若雪,刘晓晗,刘春铖,赵然,刘玉昆. 长链非编码RNA HEATR3反义RNA 1参与结直肠癌发生发展的功能及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(9): 108-115.
[2]	刘保国,宋翔,赵晓文,毛亚丽. 血清STAT5B、NKAIN1 mRNA检测在乳腺癌中的应用价值[J]. 山东大学学报 (医学版), 2025, 63(7): 68-74.
[3]	王磊,常霄,王梓萌,李娇娇,崔书君,杨飞,朱月香. 瘤内及瘤周DCE-MRI影像组学对宫颈癌患者无进展生存期的预测价值[J]. 山东大学学报 (医学版), 2025, 63(6): 45-54.
[4]	贾若曦,吕丽,刘涵云,吴寅平,李凤彩,赵泽华,王凯,范玉琛. 血细胞计数相关标志物对慢加急性乙型肝炎肝衰竭患者28天预后的诊断价值[J]. 山东大学学报 (医学版), 2025, 63(6): 89-99.
[5]	杜雪,李春霞,刘云霞,张涛. 基于MFPC-Cox的结直肠癌患者预后动态预测模型[J]. 山东大学学报 (医学版), 2025, 63(5): 101-110.
[6]	杨卫芳,徐宏,刘元涛,赵蕙琛. 促甲状腺激素受体抗体在Graves病复发中的作用机制及其临床意义[J]. 山东大学学报 (医学版), 2025, 63(4): 116-121.
[7]	刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[8]	陈文亮,王欢欢,郝金锦,弓蕊,赵强,张飞,高磊,董静逊. lncRNA PVT1表达在胃癌预后评估及恶性进展中的作用:基于列线图模型与细胞功能实验的研究[J]. 山东大学学报 (医学版), 2025, 63(10): 61-71.
[9]	郭姝画,樊扬,田风,王传新,杜鲁涛,李培龙,郭兴,徐硕. 微原纤维相关蛋白3在调控胶质瘤干细胞间充质表型转化中的作用[J]. 山东大学学报 (医学版), 2024, 62(6): 9-16.
[10]	魏闫若雪,李梓绮,刘春铖,刘晓晗,赵然,刘玉昆. 结直肠癌中SP1的瘤内异质性表达及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(5): 89-94.
[11]	刘春铖,刘晓晗,魏闫若雪,李梓绮,刘玉昆,赵然. 结直肠癌中含溴结构域蛋白9的亚细胞定位模式及其临床意义[J]. 山东大学学报 (医学版), 2024, 62(4): 24-30.
[12]	杨雪彦,吴寅平,吕丽,赵泽华,马行宇,李凤彩,王凯,范玉琛. 单核细胞与淋巴细胞比值动态变化对慢加急性乙型肝炎肝衰竭预后的诊断价值[J]. 山东大学学报 (医学版), 2024, 62(3): 61-69.
[13]	刁玉洁,林琳,李文瑄,王洲洋,江蓓,胡迎迎,刘广义. NPR预测ANCA相关血管炎不良肾脏预后及其协同多因素优化模型[J]. 山东大学学报 (医学版), 2024, 62(2): 60-68.
[14]	宋兆录,董正璇,彭传真,黄彩娜,胡克清,黄永胜,阎磊. 肾透明细胞癌中预后相关RNA编辑位点的筛选[J]. 山东大学学报 (医学版), 2023, 61(9): 69-78.
[15]	刘艳,冷珊珊,夏晓娜,董昊,黄陈翠,孟祥水. 基于影像组学参数评估376例幕上自发性脑出血患者的功能状态[J]. 山东大学学报 (医学版), 2023, 61(5): 59-67.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed